Herantis Pharma has dosed the first patients in the final cohort of its phase 1b clinical trial assessing HER-096, a ...

Kaerus Bioscience has received orphan drug and rare paediatric drug designations from the FDA for KER-0193, its lead ...

Rein Therapeutics has begun screening and recruiting patients for its renew phase 2 trial, assessing LTI-03 as a potential ...

Ellab, the provider of validation, monitoring and calibration services and solutions, has appointed Gergely Sved as its new ...

Apiary Capital has completed its investment in performance-io (PIO), a leading life sciences performance marketing and search ...

Fiona Smith-Laittan, Vice President of Global Health Strategy and Partnerships at GlaxoSmithKline (GSK), has been appointed ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

iOnctura has begun a randomized phase 1/2 study investigating its lead asset, roginolisib, in combination with dostarlimab, ...

UCB has announced that its developmental treatment DoxTM, a combination of doxecitine and doxribtimine, has been granted Promising Innovative Medicine (PIM) designation by the Medicines and Healthcare ...

For 2025, The 2025 PharmaTimes Clinical Researcher of the Year – The Americas Awards are excited to introduce a new category, Clinical Trial Administrator. This category is designed to assess the ...